AZ considers options as US gout drug deal backfires
Ironwood tears up licensing agreement after sales disappoint
Ironwood tears up licensing agreement after sales disappoint
Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.
AZ focused on sales target set by CEO Pascal Soriot.